These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29707124)

  • 1.
    Wieser V; Gaugg I; Fleischer M; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Zeimet AG; Fiegl H; Marth C
    Oncotarget; 2018 Apr; 9(25):17501-17511. PubMed ID: 29707124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
    Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
    Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
    Zhu X; Zhao L; Lang J
    Int J Gynecol Cancer; 2018 Oct; 28(8):1514-1519. PubMed ID: 30045136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-7 expression in serous ovarian carcinomas.
    Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
    Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer.
    Xue C; Zhu D; Chen L; Xu Y; Xu B; Zhang D; Jiang J
    Transl Cancer Res; 2019 Feb; 8(1):111-119. PubMed ID: 35116740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications.
    Guo L; Tang X; Wong SW; Guo A; Lin Y; Kwok HF
    Front Pharmacol; 2022; 13():1022129. PubMed ID: 36582540
    [No Abstract]   [Full Text] [Related]  

  • 9. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
    Zhu J; Wen H; Bi R; Wu Y; Wu X
    J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Alos L; Fuster C; Castillo P; Jares P; Garcia-Herrera A; Marginet M; Agreda F; Arance A; Gonzalvo E; Garcia M; Puig S; Teixido C
    Ann Transl Med; 2020 Oct; 8(19):1218. PubMed ID: 33178750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
    Fanale D; Corsini LR; Brando C; Cutaia S; Di Donna MC; Filorizzo C; Lisanti MC; Randazzo U; Magrin L; Romano R; Bazan Russo TD; Olive D; Vieni S; Pantuso G; Chiantera V; Russo A; Bazan V; Iovanna JL
    Front Oncol; 2022; 12():946319. PubMed ID: 36212445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
    Zhu X; Lang J
    J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
    Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
    Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of patients with BRCA1-associated ovarian carcinomas depends on TP53 accumulation status in tumor cells.
    Rzepecka IK; Szafron LM; Stys A; Felisiak-Golabek A; Podgorska A; Timorek A; Sobiczewski P; Pienkowska-Grela B; El-Bahrawy M; Kupryjanczyk J
    Gynecol Oncol; 2017 Feb; 144(2):369-376. PubMed ID: 27939982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
    Gatalica Z; Snyder C; Maney T; Ghazalpour A; Holterman DA; Xiao N; Overberg P; Rose I; Basu GD; Vranic S; Lynch HT; Von Hoff DD; Hamid O
    Cancer Epidemiol Biomarkers Prev; 2014 Dec; 23(12):2965-70. PubMed ID: 25392179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
    Ning XH; Gong YQ; He SM; Li T; Wang JY; Peng SH; Chen JC; Liu JY; Qi NN; Guo YL; Gong K
    Oncotarget; 2017 Jan; 8(2):3355-3363. PubMed ID: 27926518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
    Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
    J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.